Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $22.42, but opened at $21.62. Chugai Pharmaceutical shares last traded at $21.42, with a volume of 3,755 shares.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the stock. UBS Group cut shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Zacks Research upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. Finally, The Goldman Sachs Group raised shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Chugai Pharmaceutical currently has an average rating of “Moderate Buy”.
Check Out Our Latest Analysis on CHGCY
Chugai Pharmaceutical Trading Down 3.6%
Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last posted its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. The firm had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.71% and a net margin of 35.09%. On average, equities research analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current year.
Chugai Pharmaceutical Company Profile
Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.
Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.
Featured Stories
- Five stocks we like better than Chugai Pharmaceutical
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
- CAVA Earnings: The Easiest Comp of the Year Meets a Tough Valuation
- Joint Operations: Curaleaf Makes a Play for Aurora Cannabis
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
